We showed that both sgRNA-1 and sgRNA-2 cells were characterized by a significantly reduced ability to load TOPBP1 and RAD51 (Fig. 5, F and G) and were more susceptible to cisplatin or talazoparib (Fig. 5H), as well as reduced tumor volume or weight (Fig. 5I). Here, RAD51 is linked to neoplasm.